Rhythm Pharmaceuticals Reports Mixed Phase 3 EMANATE Results

Rhythm Pharmaceuticals ( (RYTM) ) has provided an update.

On March 16, 2026, Rhythm Pharmaceuticals reported topline data from EMANATE, a global Phase 3 trial of setmelanotide in four rare, genetically driven obesity subgroups, showing that none of the substudies met the pre-specified primary endpoint of BMI reduction at 52 weeks versus placebo. However, post hoc analyses indicated statistically significant and clinically meaningful BMI reductions in patients with heterozygous POMC/PCSK1 and SRC1 (NCOA1) variants who completed the 52-week regimen, while safety findings were consistent with prior experience and revealed no new signals.

The mixed outcome underscores both the challenges of expanding setmelanotide beyond currently approved monogenic indications and the potential to refine patient selection by focusing on true loss-of-function variants in specific genes. Rhythm said it will mine the EMANATE dataset to guide development of next-generation MC4R agonists bivamelagon and RM-718 and will continue exploring MC4R agonism across additional gene families flagged in earlier studies, a strategy that could protect its leadership in rare genetic obesity despite the Phase 3 miss.

The most recent analyst rating on (RYTM) stock is a Buy with a $143.00 price target. To see the full list of analyst forecasts on Rhythm Pharmaceuticals stock, see the RYTM Stock Forecast page.

Spark’s Take on RYTM Stock

According to Spark, TipRanks’ AI Analyst, RYTM is a Neutral.

Overall score reflects a mix of strong commercial traction and high gross margins with low balance-sheet leverage, but materially offset by ongoing cash burn and losses. Technicals also weigh on the score given the stock is below key moving averages with bearish momentum. Earnings-call guidance adds both upside (near-term regulatory catalysts and stated runway) and risk (higher 2026 spend and execution/inventory headwinds).

To see Spark’s full report on RYTM stock, click here.

More about Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. is a Boston-based commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, particularly syndromic and monogenic forms of obesity driven by defects in the MC4R pathway. Its lead product, IMCIVREE (setmelanotide), is approved in the U.S., European Union and U.K. to treat certain genetically confirmed obesities such as Bardet-Biedl syndrome and POMC, PCSK1 or LEPR deficiencies in patients as young as two years old.

The company is also advancing a broad pipeline that includes additional clinical programs for setmelanotide in other rare genetic obesity indications, next-generation MC4R agonists bivamelagon and RM-718, and preclinical small molecules for congenital hyperinsulinism, underscoring its strategy to dominate the niche of genetically driven metabolic and endocrine disorders. This focused portfolio positions Rhythm as a specialized player in precision obesity therapeutics rather than in broad, polygenic obesity markets.

Average Trading Volume: 721,910

Technical Sentiment Signal: Hold

Current Market Cap: $5.97B

See more data about RYTM stock on TipRanks’ Stock Analysis page.